Melatonin Receptor Agonist Drug Class List

Drugs in Drug Class: Melatonin Receptor Agonist

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Vanda Pharms Inc	HETLIOZ	tasimelteon	CAPSULE;ORAL	205677-001	Jan 31, 2014	AB	RX	Yes	Yes
Vanda Pharms Inc	HETLIOZ	tasimelteon	CAPSULE;ORAL	205677-001	Jan 31, 2014	AB	RX	Yes	Yes
Vanda Pharms Inc	HETLIOZ	tasimelteon	CAPSULE;ORAL	205677-001	Jan 31, 2014	AB	RX	Yes	Yes
Vanda Pharms Inc	HETLIOZ	tasimelteon	CAPSULE;ORAL	205677-001	Jan 31, 2014	AB	RX	Yes	Yes
Vanda Pharms Inc	HETLIOZ	tasimelteon	CAPSULE;ORAL	205677-001	Jan 31, 2014	AB	RX	Yes	Yes
Vanda Pharms Inc	HETLIOZ	tasimelteon	CAPSULE;ORAL	205677-001	Jan 31, 2014	AB	RX	Yes	Yes

Market Dynamics and Patent Landscape for Melatonin Receptor Agonists (Including Ramelteon, Tasimelteon, Agomelatine, and Vortioxetine-Offspring Sleep Indications)

Last updated: June 25, 2026

Melatonin receptor agonists used for sleep and circadian disorders split across (1) FDA-approved “melatonin-like” agents with established patent estates (notably ramelteon and tasimelteon) and (2) broader “melatonin pathway” compounds whose regulatory status is fragmented and whose IP footprints often center on specific indications, formulations, and use claims. For market entry planning, the actionable split is between late-stage brand exclusivity and the early-cycle patent walls that block generic entry: method-of-use claims for circadian rhythm and specific dosage-form or release-profile formulations. The U.S. market’s highest near-term generic threat concentrates where Orange Book listings show expiring use and formulation patents without remaining blocking patents. Where biologics are not involved, biosimilar risk is not a factor; the main litigation risk is Paragraph IV for small-molecule tablets/capsules and label carveouts tied to approved indications.

What patents protect melatonin receptor agonists like ramelteon and tasimelteon in the US?

Ramelteon (Rozerem) patent landscape: what typically blocks generics

Ramelteon is a melatonin receptor agonist marketed in the U.S. for insomnia characterized by difficulty with sleep onset. The patent estate for ramelteon commonly clusters into three blocking categories:

• Method-of-use patents tied to sleep-onset insomnia indications and circadian timing effects.
• Formulation patents directed to dosage form characteristics that control release or stability.
• Process and intermediate patents in manufacturing that can create IP barriers when courts evaluate infringement under generic “same process” theories.

Actionable takeaway for generic launch scenarios: Orange Book listings usually provide the most enforceable timing, but the enforceability often turns on whether the generic’s proposed labeling would fall within method-of-use claim scope.

Tasimelteon (Hetlioz) patent landscape: what typically blocks generics

Tasimelteon is a melatonin receptor agonist approved for non-24-hour sleep-wake disorder (N24SWD) in completely blind individuals. Its patent estate tends to be more indication-specific, with:

• Use claims tied to N24SWD treatment and circadian rhythm entrainment endpoints.
• Pediatric dosing or regimen claims where assignees sought coverage for specific age groups.
• Formulation and stability patents for the capsule dosage form.

Actionable takeaway: N24SWD is a niche label, so generic entrants often seek a narrower carveout. Litigation risk increases when the patent set includes use claims that are not easily avoided by labeling adjustments.

Agomelatine and other melatonin pathway agents: how IP usually differs

Agomelatine is often discussed as a melatonin receptor agonist with additional pharmacology; however, its U.S. commercial footprint and Orange Book presence vary by market. Where it is not Orange Book-listed for an FDA-approved reference drug with active listings, the practical IP barrier typically shifts from Orange Book-listed patents to:

• Granted patents for use and formulations in specific jurisdictions
• Supplementary “second-generation” filings covering modified dosing regimens

For business planning, the U.S. Orange Book is the reliable map only where there is an FDA-approved reference product with active patent listings.

How strong is the patent estate for melatonin receptor agonists vs. generic entry risk?

Featured-snippet answer

The strongest generic-entry friction in melatonin receptor agonists typically comes from indication-specific method-of-use patents plus formulation or dosing regimen patents that are still listed in the U.S. Orange Book near the brand’s FDA approval and subsequent “line extension” dates.

What drives strength

1. Claim type mix
   • Method-of-use claims generally create the highest barrier when the generic must match the approved label.
   • Formulation patents can block even “label-safe” generics if the proposed product still reads on claim features (release profile, excipients, particle size, or manufacturing attributes).
2. Line-extension strategy
   • Brand holders often file continuation applications covering incremental formulation changes or additional subpopulations.
3. Litigation history
   • Prior Paragraph IV cases create data on claim construction and typical court outcomes, improving infringement or invalidity forecasts.

What weakens the estate

• Patent sets dominated by narrow formulation features that can be designed around.
• Early-life patents expiring before the last listed use or formulation patents.
• Absence of unexpired blocking patents in the Orange Book tied to the specific FDA-approved indication.

When do melatonin receptor agonists lose exclusivity in the US?

Ramelteon exclusivity timing: how to think about it

Generic “loss of exclusivity” planning requires separating:

• Regulatory exclusivity (often tied to New Chemical Entity, new indication exclusivity, or specific pediatric exclusivity grants)
• Patent expiration (Orange Book listed and any unexpired continuations)

For ramelteon, the market has already moved through much of the early exclusivity window, leaving patent expiration and remaining Orange Book listings as the main timeline driver.

Tasimelteon exclusivity timing: how it differs

Tasimelteon’s exclusivity profile often extends further due to:

• Indication-driven development and label-specific claims
• Potential follow-on filings for formulations and dosing regimens

For N24SWD, remaining patent coverage tends to persist longer than broad insomnia products because the label itself is narrow and the patent strategy is built around that label.

Practical timing lens

For both products, the “real” generics calendar aligns with:

• First potential Paragraph IV filing window (derived from unexpired Orange Book patents)
• Earliest expiration date of the last blocking patent
• Any court-ordered stay, settlement designed launch date, or FDA labeling carveout

What generic entry risks exist for ramelteon and tasimelteon?

Paragraph IV pathways and typical failure points

• Indication mismatch: a generic may submit a carveout label that attempts to avoid method-of-use claim infringement.
• Design-around formulation: changes to capsule composition or dissolution profile can avoid formulation claim elements but may introduce stability or bioequivalence risk.
• Manufacturing/process differences: process claims can still matter even when the final product is bioequivalent.

Settlement-driven risks

When parties settle, generics may agree to delayed launch dates tied to:

• non-final court outcomes
• stipulations of dismissal or covenant not to sue
• agreed label language constraints

These settlements can define market availability more accurately than scheduled patent expirations.

What is the Orange Book status of melatonin receptor agonists?

Orange Book mapping method (business standard)

Orange Book status is evaluated by:

• listing drug product entries tied to the reference listed drug (RLD)
• the set of unexpired patents, categorized by type:
  • “P” patents (method-of-use)
  • “A” patents (drug substance)
  • “B” patents (drug product)
  • “C” patents (method of manufacturing)
• expiration dates and patent number metadata

What the Orange Book often shows for this class

For melatonin receptor agonists, Orange Book listings frequently contain:

• at least one method-of-use patent covering the approved indication
• one or more drug product patents connected to formulation or dosage form features
• manufacturing-process patents that can support enforcement if the generic uses a covered process

What formulations are protected by melatonin receptor agonist patents?

Ramelteon: formulation risk

Formulation coverage often addresses:

• tablet or dosage form characteristics that improve absorption
• stability and excipient selection
• manufacturing process steps

Tasimelteon: formulation risk

Tasimelteon capsule or patient-friendly dosage formulations are often protected by:

• excipient systems and dissolution control
• stability and shelf-life improvements
• manufacturing improvements

For generics, formulation risk is high when the patent claims include measurable parameters (dissolution profiles or specific compositional ranges).

What method-of-use patents cover circadian rhythm and N24SWD treatment?

How courts typically evaluate method-of-use

• Infringement depends on whether the generic’s label leads to administration in a way that falls within the claimed method steps.
• Carveout labeling can reduce infringement, but the claim scope and court interpretation determine whether the carveout is meaningful.

Ramelteon method-of-use cluster

Method-of-use claims typically target insomnia subtypes and sleep onset endpoints.

Tasimelteon method-of-use cluster

Method-of-use claims typically focus on N24SWD population constraints (including completely blind patients) and dosing schedules that align with circadian entrainment.

What patent litigation affects melatonin receptor agonists in the US?

Litigation categories

• Paragraph IV challenges to Orange Book-listed patents
• Declaratory judgment actions on non-infringement or invalidity
• Motions over claim construction (often decisive on method-of-use scope)

How litigation changes market outcomes

Litigation often results in:

• negotiated settlement launch dates
• carveout labels to avoid method-of-use coverage
• potential consent judgments on what constitutes infringement for formulation elements

Which companies are challenging or defending melatonin receptor agonist patents?

Who typically defends

Brand holders of ramelteon and tasimelteon defend through:

• patent portfolios filed by original R&D entities and later assignees
• enforcement strategies targeting both infringement and invalidity weaknesses

Who typically challenges

Generics usually challenge via:

• Paragraph IV filings at FDA
• seeking a first-to-file market premium if they can clear the blocking patents

Business implication: the challengers are less important than the specific claim set they attack. A single successful invalidity or non-infringement finding for one blocking patent can open the door even if other patents remain.

How does the competitive landscape compare across melatonin receptor agonists?

Competitive structure

• Ramelteon competes in chronic insomnia and sleep-onset difficulty frameworks, where off-label use of other sleep agents and behavioral sleep interventions influences net pricing.
• Tasimelteon competes in the highly specific N24SWD niche, where prescriber familiarity, diagnostic coding practices, and restricted eligibility drive utilization more than broad insomnia channel share.

What matters commercially

1. Patient identification cost
   • For N24SWD, diagnosis and documentation requirements can slow adoption even where efficacy is established.
2. Payor dynamics
   • Coverage criteria often require failure of other therapies or documentation of the indication.
3. Brand-to-brand substitution
   • Substitution between insomnia agents is usually higher than substitution across circadian niche indications.

What licensing deals or settlements shape market entry?

Settlement levers

For this class, settlements usually resolve:

• whether method-of-use patents are infringed by generic label language
• whether formulation changes avoid drug product claims
• timing of launch relative to patent expiration and court stay periods

Business impact

Settlements can shift launch by years. For market modeling, the settlement schedule is treated as the operative exclusivity calendar rather than just the patent expiry date.

Regulatory pathway: how FDA approval pathways affect patent risk

FDA pathway basics for small-molecule agonists

• Generics typically follow Abbreviated New Drug Application (ANDA) approaches tied to bioequivalence
• Patent risk attaches through Paragraph IV challenges when Orange Book patents remain unexpired

Label as a legal variable

For method-of-use patents, the generic’s proposed labeling is a primary driver of litigation risk:

• carveouts can reduce infringement
• if a court holds inducement based on typical prescribing patterns, carveouts can fail

What global patent coverage patterns matter for melatonin receptor agonists?

Jurisdictional differences that matter

• U.S.: Orange Book method-of-use and drug product patents drive Paragraph IV exposure.
• Europe: enforceability depends on EPC patent validity and claim construction outcomes in EPO/ national proceedings.
• Other jurisdictions: where Orange Book equivalents do not exist, enforcement focuses on granted patents and local regulatory listing systems.

Business implication: even if a U.S. blocking patent expires, other regions may preserve exclusivity via granted patents or ongoing litigation.

Key Takeaways

• Melatonin receptor agonists’ generic entry risk is dominated by Orange Book-listed method-of-use and formulation patents, not by NCE-style exclusivity alone.
• The class’s strongest patent walls typically target approved indications and dosing regimens (especially narrow circadian disorders like N24SWD).
• Market entry calendars should model settlement-driven launch dates and label carveout feasibility, because method-of-use patents can be infringed through labeling and prescribing practice.
• Commercial rivalry differs by product niche: insomnia-category adoption patterns differ materially from N24SWD patient identification and coverage restrictions.

FAQs

1. How do Paragraph IV challenges typically treat method-of-use patents for insomnia and sleep-onset claims?
2. Which melatonin receptor agonist has the highest likelihood of long-formulation patent barriers for generic capsules or tablets?
3. What is the usual role of label carveouts in avoiding infringement for circadian rhythm and N24SWD treatment claims?
4. How do manufacturing-process patent claims affect ANDA approval timing beyond bioequivalence?
5. What patent estate features most often lead to settlement agreements that delay generic launches in this class?

References (APA)

1. U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/
2. U.S. FDA. Drugs@FDA. https://www.accessdata.fda.gov/scripts/cder/daf/
3. U.S. FDA. Guidance for Industry: ANDA Submissions (Abbreviated New Drug Applications). https://www.fda.gov/